Salbroxol (ambroxol, salbutamol) tablets №40

Description

Salbroxol (ambroxol, salbutamol) tablets №40

Composition

active ingredients: ambroxol hydrochloride, salbutamol sulfate;

1 tablet contains ambroxol hydrochloride (in terms of 100% substance) – 15 mg, salbutamol sulfate (in terms of 100% substance) – 4 mg;

excipients: lactose monohydrate, crospovidone, calcium stearate, anhydrous colloidal silicon dioxide.

Dosage form

Tablets.

Basic physical and chemical properties: tablets are round, white, with a flat surface with bevelled edges and a risk.

Pharmacological group

Agents affecting the respiratory system. Medications used in obstructive airway diseases. Salbutamol combinations.
ATX code R03A K04.

Pharmacological properties

This drug belongs to the group of combined expectorant pharmaceuticals, which are used to treat respiratory diseases.
Salbutamol is a beta-2 – adrenergic agonist. It has the ability to stimulate β-two adrenergic receptors. The latter have the property of having a noticeable bronchodilator effect, concentrating in the blood vessels of the bronchi, and expanding the bronchi.
Has an invaluable property to prevent and interrupt the arising bronchospasm. Able to reduce the resistance that occurs in the airways, while the vital capacity of the lungs increases.
Salbutamol reduces the release of histamines, promotes the expansion of the coronary arteries of the circulatory system, while a decrease in blood pressure is not observed.
The drug as a whole has the property of facilitating the work of the lower parts of the respiratory system – the lungs and bronchi.
Due to the mucolytic properties of ambroxol hydrochloride, the viscosity of the sputum decreases, which improves its passage and exit, freeing the airways.

Indications

This drug Salbroxol tablets is intended for the symptomatic treatment of congestion occurring in the respiratory tract, accompanied by a cough, in diseases such as:

• bronchial asthma, incl. with bronchospasm;
• chronic obstructive bronchitis, COPD;
• emphysema of the lungs.

Contraindications

The drug Salbroxol tablets in question is not used if the patient has ever had hypersensitivity (allergy) to one of the components that make up its composition.
Do not use if the patient suffers from:

• hyperthyroidism, thyrotoxicosis;
• tachyarrhythmia, arterial hypertension;
• ulcer of the stomach and / or 12 duodenal ulcer;
• acute heart failure, heart defects, myocarditis;
• convulsive syndrome, epilepsy;
• glaucoma, pheochromocytoma;
• the threat of abortion.

Concomitant use with beta-blockers, especially non-selective ones, is contraindicated.
In pediatrics, it is not used until the age of 14.

Application during pregnancy and lactation

This drug is contraindicated for the treatment of pregnant women in the 1st trimester of pregnancy.
Lactation is suspended for the duration of treatment with this drug.

Method of administration and dosage

Recommended dosage regimen: 1 tablet 3-4 times a day. For adults, it is permissible, if necessary, to increase the dose to a maximum of 2 per dose.
The drug is taken between meals.
At least 6 hours should elapse between pills.
The duration of treatment is individual, depends on the course of the disease and is determined by the attending physician.

Overdose

Overdose with this drug can cause increased side effects in the form of:

• tachycardia, weakness;
• increased blood pressure;
• convulsions, muscle tremors.

In case of an overdose, symptomatic treatment should be applied – rinse the stomach, ensure active diuresis.
Reception of enterosorbents can improve the patient’s condition.

Side effects

The use of this drug in a patient can cause side effects in the form of:

• headache, dizziness, agitation, tremors, seizures;
• nausea, vomiting, epigastric pain, diarrhea, dysgeusia, stomach ulcers;
• dizziness, feelings of fear, anxiety;
• general weakness, tremors, seizures, tachycardia;
• arterial hypertension;
• anorexia;
• vasodilation.

Allergic reactions are possible in the form of angioedema, skin rash, allergic urticaria, itching.